PARIS- Agile Therapeutics Inc. has completed patient recruitment in its phase III clinical trial of Twirla, its investigational contraceptive patch. Aimmune Therapeutics Inc. plans to initiate an international phase III registrational trial of AR101 in children and adults with peanut allergy in early 2016.. Peanut allergy is a serious and growing h
Release date- 31082015- ALBANY, N.Y.- AMRI and Saneca Pharmaceuticals, a.s. today announced a strategic collaboration focused on the development, manufacture and marketing of a portfolio of opium-derived active pharmaceutical ingredients. Based on customer demand, AMRI will prepare the U.S. regulatory filings, and following FDA approval, will manuf
Release date- 31082015- Asahi Kasei Pharma is announcing that XIAFLEX injection for the treatment of Dupuytren's contracture has been listed on the National Health Insurance drug price standard as of today. Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement concluded in March 2011. After conducting a Phas
-Basilea Pharmaceutica Ltd. reports today that Dr. Ingrid Heinze-Krauss will retire after 15 years with the company. Prior to joining Basilea, he held various positions with increasing responsibility at Hoechst Marion Roussel in Frankfurt, Germany and at Novartis Pharma AG in Basel, Switzerland.
BioTime reported that BioTime management will present at the Rodman& Renshaw 17th Annual Investment Conference in New York City from 3 to 3:25 p.m. EDT on Thursday, September 10. According to a release, investors will receive an update on BioTime and its subsidiaries. BioTime, a provider of regenerative medicine, is a clinical- stage biotechnology
Can-Fite BioPharma reported financial results for the six months ended June 30, and updates on its drug development programs. Patent and Trademark Office granted Can-Fite a patent covering the manufacturing process for CF101 in the U.S. and the World Health Organization accepted "piclidenoson" as the proposed generic name for CF101, both important
By a News Reporter-Staff News Editor at Cancer Weekly Investigators publish new report on Drugs and Therapies. However, only three HDAC inhibitors have acquired FDA approval till date. Recently, PXD-101 obtained FDA approval for the treatment of Refractory or Relapsed Peripheral T cell lymphoma.
DGAP-News: Neovacs S.A./ Key word: Study NEOVACS RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFN-KINOID IN LUPUS 01.09. 2015/ 08:00- PRESS RELEASE NEOVACS RECEIVES FIRST REGULATORY APPROVALS FOR A PHASE IIb TRIAL OF IFN-KINOID IN LUPUS IFN-K-002 clinical trial
EQS Group-News: Polyphor AG/ Key word: Study Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibitor POL6014 for lung diseases to Phase I 01.09. 2015/ 09:00- Polyphor extends clinical development portfolio by advancing its inhaled elastase inhibi
Heat Biologics, Inc., a clinical stage cancer immunotherapy company, announced that it has enrolled the first patient in a Phase 1 b clinical trial investigating the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab in non-small cell lung cancer. Additionally, as the FDA approval of nivolumab and.
Saniona announces its intention to list the company on Nasdaq Stockholm Small Cap in 2016 and appoints CFO Thomas Feldthus as executive vice president to head up the process. Results reported from preclinical development and disclosure of Phase 1 plans for AN363. University of Pennsylvania's Treatment Research Center is granted rights to perf
Release date- 31082015- Paris- Ipsen today announced that The Lancet Neurology has published online at http://www.thelancet.com/neurology the detailed results from the Ipsen sponsored phase III randomized study showing the efficacy and safety of Dysport in post-stroke or traumatic brain injury patients with upper limb spasticity.
NEOVACS, a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that it has been granted first approvals by regulatory agencies and ethics committees in several European countries for a Phase IIb clinical trial of IFN-Kinoid in Systemic Lupus Erythematosus or lupus. Acceptance by competent authorities enabl
Novartis International AG/ Novartis receives EU approval for Tafinlar and Mekinist , first combination approved for patients with aggressive form of melanoma. *Approval based on two Phase III studies demonstrating statistically significant overall survival benefit with combination therapy vs BRAF inhibitor monotherapy* Targeted combination...
Opexa Therapeutics, Inc., a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis and neuromyelitis optica, today announced that the Company has entered into a stock purchase agreement with a private investor to fund the Company s NMO program, including its planned Phase I/II tria
By a News Reporter-Staff News Editor at Life Science Weekly- Temple University Hospital and Fox Chase Cancer Center are the only two sites in Philadelphia that participated in an international phase I, randomized clinical trial which tested the drug guadecitabine in Myelodysplastic syndromes and acute myelogenous leukemia. Jean-Pierre Issa, MD, D
Threshold Pharmaceuticals reported that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or "tarloxotinib", for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. According to a release from the company, Tarloxotinib is Threshold's proprietary, hypoxia-activated,..
ViroMed Co., Ltd. today announced that the company has received an approval from the US FDA to launch a pivotal Phase III clinical trial utilizing VM202, a proprietary DNA based biopharmaceutical, for chronic non-healing ischemic diabetic foot ulcers. This is the first gene therapy trial specifically targeting ulcers which affects millions of peopl
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Bernick, Brian A.; Cacace, Janice Louise; Persicaner, Peter H.R.; Irani, Neda; Amadio, Julia M., filed on April 20, 2015, was made available online on August 20, 2015, according to news reporting originating from Washington, D.C., by NewsRx correspo
By a News Reporter-Staff News Editor at Clinical Trials Week 60 Degrees Pharmaceuticals,, a company focused on development of therapeutics for tropical diseases, and Singapore General Hospital announced that the Hospital has received a grant from Singapore's National Medical Research Council to support a Phase II clinical trial among dengue fever
Adocia and Eli Lilly and Company reported the initiation of a Phase 1 b clinical trial evaluating BioChaperone Lispro, an ultra- rapid formulation of insulin lispro licensed to Lilly. The formulation uses Adocia's proprietary technology BioChaperone, which is designed to accelerate insulin absorption. "This new clinical study aims to further docum
Adocia reported the initiation of a Phase I clinical trial evaluating a new and more concentrated formulation of BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Eli Lilly and Company. Our goal is to test the potential bioequivalence of these two formulations "says Olivier Soula, Adocia's R&D Director and Deputy General
The Alliance Foundation Trials, the Austrian Breast& Colorectal Cancer Study Group and Pfizer have launched the Palbociclib Collaborative Adjuvant Study, or PALLAS. The company said the global Phase 3 clinical trial for patients with early-stage breast cancer is being conducted in conjunction with Breast International Group, German Breast Group,...
Agile Therapeutics, Inc. a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla , its investigational contraceptive patch.
AGTC filed an Investigational New Drug application with the U.S. Food and Drug Administration in March to conduct a Phase I/II clinical trial of the company's gene therapy product candidate for the treatment of XLRS. Utilizing technology licensed from the University of Florida, AGTC's XLRS product candidate uses an AAV capsid with surface residues